Last reviewed · How we verify

Cefazolin Preoperatively

Aultman Health Foundation · FDA-approved active Small molecule

Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.

Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Surgical site infection prophylaxis in preoperative settings.

At a glance

Generic nameCefazolin Preoperatively
Also known asAncef, Kefzol
SponsorAultman Health Foundation
Drug classFirst-generation cephalosporin
TargetPenicillin-binding proteins (PBPs)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Cefazolin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It is bactericidal and has broad activity against gram-positive cocci and some gram-negative bacteria. When administered preoperatively, it provides prophylaxis against surgical site infections by achieving adequate tissue concentrations during the surgical procedure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: